Background:
Everolimus is approved for treatment of antivascular endothelial growth factor (VEGF)-refractory patients with metastatic renal cell carcinoma (mRCC). Clinical trials rarely mirror treatment reality. Thus, a broader evaluation of everolimus is valuable for routine use. Patients and Methods: A German multicenter non-interventional study documented mRCC patients starting everolimus after failure of initial VEGF-targeted therapy. Primary endpoint was effectiveness, defined as time to progression (TTP) according to investigator assessment (time from first dose to progression). Results: Of 382 documented patients, 196 were included in this interim analysis. In the efficacy population (n = 165), median TTP was 7.0 months (95% confidence interval (CI) 5.1-9.0). Among patients with < or ≥ 6 months of previous VEGF-targeted therapy, median TTP was 6.6 months (95% CI 3.8-not estimable) and 7.4 months (95% CI 4.6-9.6), respectively. Most common adverse events were anemia (13%) and dyspnea (14%). Physicians assessed high tolerance and documented high adherence to everolimus therapy (approximately 97%). Conclusion: In routine clinical practice, everolimus is effective, as measured by median TTP (longer than median progression-free survival in RECORD-1 trial), and well tolerated. Our results support everolimus use in anti-VEGF-refractory patients with mRCC.
Introduction
Everolimusisanorallyadministeredselectiveinhibitorofthe mammaliantargetofrapamycin(mTOR),aserine-threonine kinasewhichisup-regulatedinseveraltypesofhumancancer cells.Inhibitionoftumorcellproliferationandgrowthaswell asareductionofmetabolisminsolidtumorsareclasseffects of everolimus. In addition, mTOR inhibition is associated withanti-angiogenicactionsthroughreductionofendothelial cellproliferation,vascularendothelialgrowthfactor(VEGF) levels,andtheresponseofendothelialvascularcellstostimulation by VEGF [1, 2] . These mechanisms of action may be beneficial, especially in patients who fail initial VEGFtargetedtherapy.
In a multicenter, randomized, double-blind, phase III study, everolimus 10 mg/day demonstrated clinical benefit overplaceboinpatientswithmetastaticrenalcellcarcinoma (mRCC),whohadfailedprevioustherapywithsunitiniband/ orsorafenib.Priortreatmentwithinterferon-alphaandbevacizumab was allowed. Everolimus significantly prolonged medianprogression-freesurvival(PFS)perRECISTcriteria by3months;from1.9months(95%confidenceinterval(CI) 1.8-1.9months)withplaceboto4.9months(95%CI4.0-5.5 months) with everolimus (p < 0.001) [3] . Median overall survival (OS) was 14.8 months in the everolimus group and14.4monthsintheplacebogroup(p=0.162);themajority of patients in the placebo group crossed over to receive everolimus upon progression. A rank-preserving structural failure time model accounted for the crossover effect and calculatedamediansurvivalforpatientsintheplaceboarm of10.0monthsinsteadof14.4months.
This non-interventional study (NIS) was initiated shortly aftereverolimus(Afinitor ® ,NovartisPharmaGmbH,Nuremberg, Germany) was approved in August 2009 for the treatment of patients with advanced RCC, who had progressed duringoraftertreatmentwith1VEGF-targetedtherapy [4] [5] [6] .SinceclinicalphaseIIItrialsrarelymirrortreatmentreality, the objective of the study was to systematically evaluate theefficacyandsafetyofeverolimusinpatientswithmRCC, whofailed1previousVEGF-targetedtherapy(VEGFreceptor-tyrosine kinase inhibitor (VEGFr-TKI) or anti-VEGF anti body)inroutineclinicalpractice.
Patients and Methods

Study Design and Patient Population
Thisprospectivemulticenter,non-interventional,observationalstudywas initiated following commercial availability of everolimus for the treatmentofmRCCinGermany.Thestudywasperformedinaccordancewith the German drug law and the relevant guidelines of German health authorities and the pharmaceutical industry for conducting a NIS. The observational plan was approved by the local ethics committee of the scientificheadofthestudy,andtherespectiveresponsibleethicscommittees at each participating site were informed. Patients provided written informedconsentpriortostartofdocumentation.
Patients were entered at centers across Germany between August 2009andJanuary2012.Patients≥18yearsoldwithmRCCcouldbedoc-umentedifthetreatingphysicianhaddecidedtoprescribeeverolimusin accordancewiththesummaryofproductcharacteristics(SmPC) [7] ,i.e. followingfailurewith1VEGF-targetedtherapy(e.g.sunitinib,sorafenib, pazopanib, or bevacizumab). Previous exposure to cytokine-based regimenssuchasinterleukin-2,interferon-alpha,orbevacizumabplusinterferon-alphawasallowed.PretreatmentwithasecondVEGFr-TKIfora periodof≤1monthbecauseofintolerabilitywasalsopermitted.Patients couldbeincludediftheirtreatmentwitheverolimushadbeenongoingfor < 90 days, or ≤ 1 imaging follow-up investigation had been performed since the start of everolimus. Patients received oral everolimus 10 mg oncedailyaccordingtousualroutinepracticeasoutlinedintheSmPC. Documentation of each patient was performed in accordance with routineassessmentsforthedurationofeverolimustreatment.Becauseof the non-interventional nature of the study, time point and method of determination of disease progression were not defined but instead followedroutinemedicalcareasdecidedbythephysician.Tumorresponse andprogressionwereassessedbythetreatingphysicianandtheradiologist according to the hospital's established practice. In accordance with the observational plan, enrolment was terminated at 382 patients, on January20,2012.Alsoinaccordancewiththeobservationalplan,thefirst interimanalysiswasperformedafterenrollmentof100patientswhowere documentedfor≥3monthsorhaddocumentedtherapydiscontinuation and reported elsewhere [8] . A second interim analysis (reported here) was performed after the patients analyzed in the first interim analysis werefollowedupforanadditional10months.Patientpopulationswere definedas'totalpopulation'whichincludedpatientsdocumentedwithin 3monthsofstartingtreatmentwitheverolimus;'safetypopulation'which includedpatientsfromthetotalpopulationwhohaddocumentedintake/ prescription of everolimus and ≥ 1 post-baseline assessment; 'efficacy population'whichincludedpatientsfromthesafetypopulationwhowere documented before or < 90 days after initiation of everolimus and had received a single VEGFr-TKI or a second VEGFr-TKI for ≤ 1 month before everolimus; '1 previous VEGFr-TKI population' which included patients from the efficacy population who were treated with 1 previous VEGFr-TKI;'<6monthsdurationofpreviousVEGF-targetedtherapy population' which included patients who received 0 to < 6 months of previous treatment with VEGFr-TKI therapy and/or bevacizumab; and '≥ 6 months duration of previous VEGF-targeted therapy population' whichincludedpatientswhoreceived≥6monthsofprevioustreatment withVEGFr-TKItherapyand/orbevacizumab.
Objectives
Studyobjectiveswereeverolimuseffectivenessanddurationoftherapy. Effectivenesswasmeasuredbytimetoprogression(TTP),whichwasdefinedastimefromfirstdoseofeverolimustodiseaseprogressionaccording to the investigator assessment. Information on treatment regimens beforeandaftereverolimuswasalsocollected.Additionalobjectivesincluded Karnofsky performance status (KPS) in patients treated with everolimus, and assessment of adherence and tolerability at each visit duringroutineadministrationofeverolimus.
Statistics
Duetothenatureofthenon-interventionaldesign,therewasnoformal samplesizecalculation.Thus,samplesizewasbasedondiseaseincidence, sample size in comparison to the overall population, and the expected recruitment within the enrollment period. The sample size comprised >10%ofthetotalpopulation,consideringapproximately2,500-3,000pa-tients in need of targeted therapy after initial VEGF-targeted therapy (VEGFr-TKI or anti-VEGF antibody) per year. A detailed statistical analysis plan (SAP) was developed prior to the start of the study and finalizedbeforethefirstinterimanalysis.Thestudywasanalyzedusing descriptivestatisticalmethods.
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EverolimusinmRCC: ResultsofaNon-InterventionalStudy 97 witheverolimusinitiation,1patientdidnotreceivetreatment, 10 patients met the criteria for enrolment after everolimus initiation,and20patientshadreceived≥2VEGFr-TKIsprior toeverolimusinitiation.Baselinepatientanddiseasecharacteristics are summarized in table 1. The majority of patients weremale(75%)andhadclearcellhistology(92%).Atbaseline,amedianof2organsystems(range1-7)wereinvolvedin metastatic spread, most frequently involving the lungs and skeletalsystem.Themainreasonforinitiatingeverolimuswas progressionduringprevioustherapy(84%),andthemajority ofpatientsenrolledhadreceivedonly1previousantineoplas-tic therapy (72%, table 2). The most common previous VEGF-targetedtherapywassunitinib(80%),withamedian (range) treatment duration of 9.0 (0.0-49.4) months among thetotalpopulation(table2).Median(range)treatmentdurationofprevioustherapywithsorafenib,bevacizumab(given asmonotherapyorincombinationwithinterferon-alpha),and cytokines was 5.9 (0.1-41.4) months, 4.0 (0.3-20.7) months, and7.1(4.0-13.0)months,respectively.
Effectiveness
According to Kaplan Meier estimates, median duration of everolimustherapyfortheefficacypopulationwas7.3months (95%confidenceinterval(CI)4.7-10.9months).Amongthe subpopulations of patients who had received < 6 months or ≥ 6 months duration of previous VEGF-targeted therapy, mediantreatmentdurationswitheverolimuswere7.5months (95%CI4.9-11.1months)and7.4months(95%CI4.8-10.9 months), respectively (table 3) . At the time of data cut-off, 60patientsremainedoneverolimus(31%),andtreatmenthad VEGFr-TKI population (n = 121), < 6 months duration of previous VEGF-targeted therapy population (n = 69), and ≥ 6 months duration of previous VEGF-targeted therapy population (n = 121). At the data cut-off of this analysis ( September 30, 2011), the median observational time was 142days(range9-665days)forthetotalpopulation.Among documentedpatients,186individualswereobservedstarting
Bergmann/Goebell/Kube/Kindler/ Herrmann/Janssen/Schmitz/Weikert/ Steiner/Jakob/Staehler/Steiner/ Overkamp/Albrecht/Guderian/Doehn been discontinued in the remaining patients due to disease progression(35%),adverseevents(AEs,18%),death(11%), orotherreasons(table4).Among136patientswhohaddis-continuedeverolimustreatmentatthetimeofanalysis,59pa-tients (45%) received additional anticancer treatment after everolimus,mostcommonlyaVEGFr-TKIsuchas sorafenib, sunitinib,orpazopanib.Intheefficacypopulation(n=165), median TTP after initiation of everolimus was 7.0 months (95%CI5.1-9.0months)( fig.1 ).Resultsweresimilarinpatientswhoreceivedexactly1previousVEGFr-TKI(n=121) (medianTTP7.1months;95%CI5.5-9.0months).Inasubanalysisoftheefficacypopulationbydurationofpriortherapy ( fig.2) This NIS represents the first systematic evaluation of everolimusinroutineuseamongpatientswithadvancedRCC after failure of 1 VEGF-targeted therapy. Treatment with everolimuswasassociatedwithamedianTTPof7.0months inthisNIS.Althoughtheendpointscannotbedirectlycompared, a median PFS (RECIST) of 4.9 months (central review)or5.5months(investigatorassessment)wasreportedin theplacebo-controlled,phaseIIIRECORD-1study [3] .The longerTTPassociatedwitheverolimusinthisNIScouldhave resultedfromthesubjectivedefinitionofprogression.
A pre-planned subgroup analysis of RECORD-1 demonstrated that treatment with 2 previous VEGFr-TKIs was associatedwithashortermedianPFSforeverolimusthantreatmentwith1previousVEGFr-TKI(4.0monthscomparedwith 5.4months,respectively) [15] .PatientstreatedonlywithsunitinibbeforeeverolimusexhibitedamedianPFSof4.6months inposthocanalysisofRECORD-1 [15] .InthisNIS,73%of patientsreceivedexactly1previousVEGFr-TKI,whichcorrelatedwithamedianTTPof7.1months.
ThedurationforwhichapatienthadreceivedVEGF-targetedtherapy(<6monthsor≥6months)didnotappearto affect the duration a patient would receive everolimus. MedianTTPwitheverolimuswaslongerforpatientswhohada longerdurationofpreviousVEGF-targetedtherapy,suggestingthatpatientswhobenefitfromalongdurationofprevious VEGF-targeted therapy may also experience slightly prolonged benefit from everolimus. This observation is in line withapreviousreportshowingthatprolongedPFSwithfirstlineVEGFr-TKItherapymaypredictimprovedsurvivalwith everolimus [16] . In contrast, short treatment durations with VEGF-targetedtherapyandeverolimusmaybeattributable toaggressivetumorbiologyoftheunderlyingdisease.
ThesafetyprofileofeverolimusinthisNISwasconsistent with previous reports [3, 17, 18] , and everolimus was well tolerated in the majority of patients. In RECORD-1, 7% of patientsrequired≥1everolimusdosereductionand38%re-quired treatment interruption [3] . In this study, dose adjustmentwasmorecommon(26%),butfewerpatientsrequired treatment interruption (13%), suggesting that dose adjustmentiseffectiveinaroutineclinicalsettingtomanageeverolimus-relatedtoxicity.
The incidence of all AEs was considerably lower in this NIS compared with clinical studies of everolimus. Possible reasons for the lower incidences of AEs reported in routine clinical practice are under-reporting by participating physicians compared with clinical trials, frequency of follow-up visits,growingexperienceswiththeuseofeverolimusinpatientswithmRCC,andlessseverediseasestatus.OtherlimitationsofthisNISincludethelimitedmedianfollow-uptime compared with the calculated treatment duration and TTP, verificationofsourcedatafor25%ofpatients,andthatinterventions in terms of pre-specified procedures such as visit schedulingorimagingcouldnotbedefinedduetotheobservationalnatureofthestudy.Althoughthenon-interventional patients and as a SAE for 2% of patients. Everolimus dose adjustments were required for 26% of the total population, andtreatmentinterruptionswerenecessaryfor13%(n=26) ofthepatients,withamediandurationof16days(range5-53 days).Timeto≥10%reductioninKPSaccordingtoKaplan-Meierestimateswas7.3months(95%CI5.6-10.1months)for thesafetypopulation.Overall,>75%ofphysiciansreporteda highassessmentoftolerancetoeverolimusandhighdegreeof adherencetotherapy(approximately97%).
Discussion
Multiple targeted agents are available for the treatment of patientswithmRCC,posingthequestionofhowtobestuse these agents in sequence [5, 9] . Research has suggested that mechanismsofresistancetoanti-VEGFtherapymightpartly be overcome by a consecutive VEGF-targeted agent [9] . VEGF-targeted agents available for treatment of patients with mRCC include the VEGFr-TKIs axitinib, pazopanib, sorafenib, and sunitinib and the VEGF inhibitor bevacizumab.BasedonresultsofthephaseIIIAXIStrial [10] ,axitinib was recently approved by the European Medicines Agency for treatment of patients with mRCC, who failed first-line therapy with cytokines or sunitinib [11] . Pazopanib is approved for treatment of patients with mRCC either as firstline or after cytokine therapy, and is currently being evaluated in a phase II trial of VEGFr-TKI-refractory patients with mRCC (clinicaltrials.gov identifier NCT01157091). These results may offer increased insight into sequential VEGFr-TKI treatment. Availability of compounds with different modes of action provides the opportunity to change mechanistic classes with different lines of treatment. The mTOR inhibitor everolimus is approved for treatment of patientswithmRCC,whofailedinitialVEGFr-TKItherapy, basedonresultsofthephaseIIIRECORD-1trialwhichdem-onstratedtheefficacyofeverolimusinthispatientpopulation [3] . Temsirolimus is available for first-line treatment of patientswithmRCC,whoareofpoorprognosis.Clinicaltrials evaluating sequential treatment with VEGFr-TKIs agents versusmTORinhibitorsinadirecthead-to-headfashionwill further inform physicians and patients about treatment choices after first-line treatment with a VEGFr-TKI. The INTORSECTtrialrecentlyrevealedthattemsirolimusoffers no significant benefit over sorafenib in patients who failed first-line therapy with sunitinib (clinicaltrials.gov identifier NCT00474786) [12] .TheRECORD-3trialiscurrentlyassess-ingthesequencesofeverolimusandsunitinibversussunitinib and everolimus in treatment-naive patients with mRCC (clinicaltrials.gov identifier NCT00903175). In addition, clinicalexperiencehasshownthatchangingthemodeofaction, such as sequential treatment with a VEGFr-TKI, an mTOR inhibitor, and a VEGFr-TKI, is clinically beneficial [13, 14] .
character of a NIS results in limited data quality compared with a clinical trial, crucial insights into the value of everolimusinthetreatmentofmRCCcanbegainedbythistoolfor structuredevaluationofroutinemedicalcare.
Conclusion
This NIS interim analysis adds evidence from daily medical practice to support the favorable benefit/risk profile of everolimus as reported from the randomized RECORD-1 phase III study. Physicians should be aware that prolonged duration of previous VEGF-targeted therapy may lead to longermedianTTPfortheirpatientswithmRCC,whofailed initial VEGF-targeted therapy and subsequently received everolimus; the safety profile of everolimus is consistent regardless of previous treatment duration. Results of this NIS provideevidenceofthesafetyandeffectivenessofeverolimus useinroutineclinicalpracticefortreatmentofpatientswith mRCC,whofailedinitialVEGF-targetedtherapy.
